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C ritically colonised (wounds-at-risk) or locally infected wounds pose a common therapeutic challenge in the field of wound healing. [1] [2] [3] [4] [5] [6] However, in recent years, there has been debate regarding the appropriateness and efficacy of the various local and systemic methods available for wound disinfection. 4, 5, 7, 8 Topical antimicrobial substances, such as antiseptics like povidone-iodine, octenidine or polihexanide, are increasingly used to treat local wound infections. 4, 5, [7] [8] [9] [10] Antimicrobial dressings are another common intervention, with a huge variety of silver-containing dressings (Ag) available for treating wound infections and critical colonisation. 6, [9] [10] [11] [12] [13] In addition to Ag, polihexanide-containing biocellulose dressings (Suprasorb X+PHMB, Lohmann & Rauscher GmbH & Co. KG) (BWD+PHMB) have also been shown to exhibit antimicrobial properties. 7, 8, [14] [15] [16] [17] [18] [19] [20] Although both types of dressings are widely used to treat critically colonised (wounds-at-risk) or locally infected wounds, very little direct comparative data exist on their therapeutic capacity, specifically their antimicrobial efficacy. 6, 15 For this reason, a prospective, randomised, controlled, multicentre trial was developed to comparatively analyse the efficacy of Ag dressing and Suprasorb X+PHMB (hereafter referred to as BWD+PHMB) when used for the treatment of critically colonised and locally infected wounds.
A common problem, reported to be associated with local wound infection, is pain. It is often a marker for critical bacterial wound burden, 1, 2 together with immobility, a feeling of helplessness, and diminished social interactions. [21] [22] [23] [24] [25] These problems may induce stress, anxiety and depression, resulting in a further delay of wound healing. research s t h i s a rt i c l e i s r p e r i n t e d f ro m t h e j o u r n a l o f wo u n d c a r e v o l 2 1 , n o 1 , J a n u a ry 2 0 1 2
Moreover, there are reports of under-treatment of pain in patients with critically colonised or locally infected wounds. 23, 24 Effective treatment of these wounds should not just reduce bacterial burden, but also reduce wound pain and improve patients' quality of life. Therefore, these symptoms, together with reduction of wound bacterial burden, were chosen to be the assessed outcomes of our study.
Method
The study was conducted in three study centres: 
Participants
Patients were considered eligible for inclusion if they presented with an initial VAS pain score ≥4 (0=no pain, 10=unbearable pain) and had a woundassociated semi-quantitative bacterial load, as defined by the microbiological assessment of a wound swab, of ++ or greater.
26
Bacterial count was assessed using wound swabs according to Levine et al., 26 such that, after mechanical cleansing of the wound bed with a saline swab, a wound swab was performed over the wound bed area of 1×1cm (Fig 1) . The semi-quantitative results were scored as 0=no burden, + =slight bacterial burden, ++ =moderate bacterial burden, and +++ =high bacterial burden.
While clinical symptoms are universally acknowledged to be the ultimate indicators of critical colonisation/local infection, in German-speaking countries the latter are also considered to be associated with a bacterial load of ++ or greater.
Wounds of all aetiologies were included in the study; there were no age or gender limitations. The exclusion criteria comprised: l Signs of systemic wound infection [27] [28] [29] l Systemic antibiotic therapy l Known allergies to any of the components of the products used l Pregnancy or lactation l Wound size >200cm 2 . Eligible patients were included by a randomisation schedule conducted sequentially, such that the first patient was allocated to BWD+PHMB, the second to Ag, the third to BWD+PHMB and so on. If patients had more than one wound, they were only included in the study (in the same group) if the aetiology was the same and the wounds were on the same limb.
The treatment group (arm 1) received anti microbial wound treatment with BWD+PHMB. If there was moderate exudate, then either a foam (Suprasorb P, Lohmann & Rauscher GmbH & Co KG) or, if the patient was receiving compression therapy, an absorbent dressing (Vliwazell, Lohmann & Rauscher GmbH & Co KG) was used as the secondary dressing.
The control group (arm 2) was allocated to Ag dressings. Ag dressings used were Acticoat, Acticoat Absorbent (both Smith & Nephew), Aquacel Ag (ConvaTec), Biatain Ag (Coloplast), Silvercel (Systagenix Wound Management) and Urgotul Ag (Urgo GmbH). Dressing selection was determined by the protocols used at the participating centres. If necessary, secondary foam or absorbent dressings were used, as in the treatment group.
In both groups, patients with venous leg ulcers (VLUs) underwent vascular assessment (ABPI, fuller Doppler or Duplex scan) and were treated with compression, up to 60mmHg measured at B1, with a short-stretch bandaging system (Rosidal sys, Lohmann & Rauscher GmbH & Co KG), if indicated. Dressing changes occurred every second day and every third day over the weekends. The treatment duration was again based on local protocols, and was generally 10-14 days. However, the total study period was 28 days, as it was assumed that this would be sufficient to observe a reduction in bacterial burden, while also preventing overuse of the antimicrobials.
The required sample size was obtained based on a sample calculation using Pearson's chi-squared test for α=0.05 and power=80%, at the 0.05 significance level. To detect a 20% difference or more between groups on pain reduction, comparing day 0 and day 28 results, 25 patients per treatment group was identified as sufficient, 30 assuming there would be no significant population differences (normally distributed) at the start of the study and that there was a standard normal distribution in both groups.
Ethics committee approval was obtained from the local review board of the Federal Academic Teaching Hospital of Feldkirch, Austria and from the ethics committee of Canton Thurgau, Switzerland. All patients gave written informed consent prior to the commencement of the study.
outcomes
The primary outcome for the study was patientreported total mean pain score using a 10-point visual analogue scale (VAS), comparing day 0 (start) and day 28 (end), and pain reduction over time, scored on days 1, 3, 7, 14 and 21. The pain score included the pain levels experienced both during the day and at night (retrospectively), together with assessment of pain before dressing removal and 15min after completing the dressing change. Pain reduction was analysed per patient, per group and between groups. Patients were blinded as to their treatment allocation.
Secondary outcomes included the antimicrobial effect of the dressings used in the two treatment arms, wound bed evolution and periwound skin condition, quality of life of the patients, and the clinicians' satisfaction with the given treatment. Frequency of assessments was the same as for pain.
Bacterial count was assessed using wound swabs according to Levine et al., 26 as described above. Wound exudate was assessed as mild/moderate/ high by trained, experienced clinicians, using a clinical scoring tool.
Wound bed evolution was assessed visually, objectively (using the digital Dutch Wound Care Society colour classification system) and as part of the Würzburger quality of life score. 31 The condition of the periwound skin area was considered an important parameter for the tolerability of the applied dressings.
32 As such, the presence and rating of the adverse reactions of maceration and redness (4-point scale: none, slight, moderate and high), together with a general score on tolerability (4-point scale: very good, good, moderate, poor), was assessed on days 0, 1, 3, 7, 14, 21 and 28 by a clinical investigator blinded to the treatment allocation using a validated clinical scoring tool, developed in dermatology, based on the global assessment scale (IGA).
33
For information about the clinicians' opinion on the treatment, they were asked to score, on a 6-point scale (very good, good, moderate, sufficient, insufficient, poor):
...throughout the day and night.
Unlike elastic systems, Actico ® gives you low resting pressures at night -making bedtime a lot more tolerable. Quality of life was assessed using the Würzburger quality of life score, 31 which is a questionnaire consisting of 19 different questions related to patients with chronic wounds. It has been shown to be a more disease-specific quality-of-life assessment tool than generic questionnaires, such as SF-36 and the Nottingham Health Profile. 34, 35 Since wound pain was the study's primary parameter and was scored separately, the section on pain was removed and we used a modified Würzburger quality of life score with 17 questions.
Statistical analysis
Descriptive statistics, including mean, median and standard deviation (SD), were calculated for the demographic and clinical characteristics of the patients. The Wilcoxon rank-sum test was used to test for differences between the two treatment groups.
As it was normally-distributed, the analysis of the primary outcome, pain relief, was conducted using paired t-test, comparing baseline pain (day 0) with day 28 (end) and pain relief over time at visits day 1, 3, 7, 14 and 21, per patient, per group and between groups. Significance was taken as p<0.05.
36 Data processing and analysis were performed independently by a clinician blinded as to the treatment group and uninvolved in any other aspect of the trial.
The analyses of the secondary outcomes, antimicrobial efficacy of the dressings, wound bed evolution and periwound skin condition, patient-reported quality of life and the clinicians' satisfaction with the given treatment were conducted using either paired t-test, for normally-distributed data, or CochranMantel-Haenszel test, Fisher's exact test or Wilcoxon rank sum test, for ordinal or non-normal data. All data were as last value carried forward (LVCF).
Results
Fifty patients were recruited into the study, of whom 38 (BWD+PHMB, n=21; Ag, n=17) with a total of 42 wounds (BWD+PHMB, n=24; Ag, n=18) were included in the analyses. Patients with multiple wounds were distributed evenly between the two groups, with two patients with two wounds on their leg in either treatment arm. While the target sample size was not achieved (n=50), the study was not extended to recruit more patients, as the deadline had passed and the additional costs due to administration and an extended study period were not considered to be justified by the recruitment of additional patients. Three protocol violations were reported, whereby a dressing outside the scope of the study was applied, due to staff issues. In the BWD+PHMB treatment arm, one patient was excluded from the study due to protocol violation and three were lost to followup (Fig 2) . Eight patients were not eligible for analyses in the Ag treatment group (two protocol violations, one lost to follow-up and five withdrawn at the patients' request; Fig 2) . All wounds, with the exception of one, in the BWD+PHMB group (abdomen), were located on the lower leg and were primarily VLUs (Table 1) .
Participants had mean ulcer duration of 3.4 ± 5.9 years (BWD+PHMB, 3.2 ± 7.8 years; Ag, 3.6 ± 8.7 years). There were no statistically significant differences between the baseline characteristics for the patients in the two groups (p > 0.1; Table 1 ).
At day 0 (start), patients in the BWD+PHMB group reported a mean VAS pain score of 6.13 ± 1.43, while those in the Ag arm had a score of 5.42 ± 1.43. During the 28-day follow-up period, comparing day 0 vs day 28 scores, pain levels significantly reduced for both BWD+PHMB and Ag (paired t-test, both p < 0.0001). When comparing VAS scores between the two groups, there was already a significant improvement in VAS scores before dressing change in the BWD+PHMB group, compared with the Ag group, by day 1 (paired t-test, p=0.03). VAS scores continued to decrease by significantly greater amounts and faster over the 28-day study period for BWD+PHMB compared with Ag-treated patients (Fig 3) .
All the patients included in the present study presented with critical colonisation or locally-infected ulcers, with, predominately, a very high bacterial load of +++. Twenty-five different species of bacteria were identified in the included wounds, among which Staphylococcus aureus occurred most frequently (37% of the wounds), followed by Enterococcus (16%), Streptococcus (5%) and Klebsiella (5%; Table 1 ).
Although a decrease of the critical bacterial burden to harmless contamination or even eradication was observed in both groups, BWD+PHMB-treated patients demonstrated a significantly faster reduction. By day 3, 25% of wounds showed a reduction of the bacterial load to +/0 (positive culture from either one or no streak areas, Fig 1) in the BWD+PHMB group, compared with 0% in the Ag group; this difference in reduction between the two groups was significant (Fisher's exact test, p=0.03). By day 28, this increased to 50% of wounds in the BWD+PHMB-treated group, compared with 28% of the wounds in the Ag-treated group, although this was no longer statistically significant (Fisher's exact test, p=0.764).
With the reduction of bacterial load to +/0, total pain had also reduced (Fig 4) . When looking at the number of ulcers that showed complete eradication of pathogenic bacteria, the same trend was noted; at day 28 there were significantly more eradicated ulcers in the BWD+PHMB arm compared with the Ag treatment arm (Cochran-Mantel-Haenszel Test, p=0.0009; Fig 5) . There was no significant difference between the two groups in wound evolution, which was used to measure healing time. Baseline vas ¶ score total 5.5 ± 1.4 5.4 ± 1.4 (median ± sd) day 6.3 ± 1.2 5.1 ± 1.4 night 6.6 ± 2.5 5.7 ± 2.4 Before dressing change 5.9 ± 2.4 4.4 ± 2.7 after dressing change 4.3 ± 2.8 4.9 ± 2.5
Baseline bacterial burden ++ 6 (25%) Regarding the condition of the periwound skin, slight maceration was noted by the clinician in the BWD+PHMB group at day 7 (mean score=1.2), which decreased during the study period to a mean score of 0.8 by day 28. In the Ag group, there was even less maceration and it showed a significant reduction over the study period, with a mean score at 0.5 at day 1 and of 0.1 at day 28 (Cochran-Mantel-Haenszel test, p < 0.0001). Redness of the periwound skin reduced during the study period in both groups, with a significantly larger reduction in the BWD+PHMB treated group (Cochran-Mantel-Haenszel test, p < 0.006). At day 0, the mean score in the BWD+PHMB group was 2.1, which reduced to 1.2 by day 28; in the Ag group, the score was 1.9 at day 1 and reduced to 1.5 by day 28.
Both the BWD+PHMB and the Ag dressings were very well tolerated; for the BWD+PHMB group, at day 1, the mean score was 1.3 and, at day 28, it was 0.8. For the Ag group, the mean score at day 1 was 1.6 and 0.1 at day 28. Investigators gave good reports on both dressings, with all questions related to this topic showing a median score of 1-2 (6-point scale). While there was no significant difference with regard to the general assessment and the satisfaction scored between the two groups, handling and conformability of the dressings was rated significantly better for BWD+PHMB, whereas Ag had significantly better ratings for its ease of use (Cochrane-Mantel-Haenszel test, both p < 0.005). The dressings used in both groups contributed to an improvement of various aspects of the patients' reported quality of life with the same four sub-scores improving significantly over the study period (Q1, 2, 3 and 14;
31 Cochrane-Mantel-Haenszel test, p < 0.05). Notably, BWD+PHMB also showed two more significantly improved sub-scores (Q5 and 15).
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No adverse or severe adverse events occurred during the study period. There was no development of a systemic infection noted in either of the treatment groups.
Discussion
Identification and treatment of critically colonised and locally-infected wounds is subject to strict rules and guidelines. 28, 29 Specifically, therapeutic use of local antimicrobials, either as antiseptic solutions or incorporated into dressings, must be of limited duration to prevent bacteria from forming an immunity. 4 As the present study was not designed as a healing study, but aimed to target the entire range of parameters related to the treatment of critically colonised (wounds-at-risk) and locally-infected wounds, the study period was set at 28 days.
BWD+PHMB had been previously shown to be clinically effective in the treatment or prophylaxis of local infections in burns and trauma wounds. 15, 17, 20 Similar efficacy has been demonstrated for Ag-treated wounds.
9-12 The present study compared the antimicrobial efficacy of BWD+PHMB and Ag applied in critically colonised (wounds-at-risk) and locallyinfected wounds. The results show that BWD+PHMB and Ag reduced and/or eradicated the critical bacterial wound burden. However, the BWD+PHMB-treated group demonstrated significantly faster action (p=0.03) and greater reduction in bacterial burden (p < 0.0009). Notably, despite the fact that all included wounds were at risk of developing systemic infections, no such systemic infections were noted, suggesting that BWD+PHMB and Ag not only exhibit therapeutic effects, but also prophylactic antiinfectious ones. Multiple swabs, taken at each visit from all study ulcers, does not reflect the everyday clinical management of locally-infected wounds. With this limitation in mind, it is useful to have another clinical marker to identify wounds with a critical bacterial load in need of prompt action. As wound pain has been suggested to indicate the presence of a critical bacterial wound burden, 3 patient-reported pain was selected as the primary outcome measure, in order to evaluate its correlation with wound infection. Indeed, along with the reduction of the bacterial load, a substantial and significant reduction in VAS pain scores were noted in both treatment arms.
Following treatment with BWD+PHMB, Piatkowski et al. reported a better and faster pain reduction in patients with superficial burns compared with those treated with silver-sulphadiazine cream.
15 Superior pain reduction was also shown when using BWD or BWD+PHMB on patients with painful venous leg ulcers, as well as on paediatric patients with painful trauma wounds. 16, 17 These reports, as well as the fact that VAS pain scores decreased significantly over the course of the study, support the assumption that the water-rich nature of the bio cellulose dressing, with its physical cooling effect, may also have contributed to the pain reduction. However, further research is required to confirm this mechanism of action.
limitations
The recruitment target for this study of 50 patients was not achieved and the calculated statistical power may have been compromised. However, the use of objective parameters, such as bacterial analysis, together with more subjective outcomes, made it possible to show trends that were consistent and clinically meaningful.
Furthermore, while the statistical analyses conducted were appropriate, a large number of timepoints were included in the analyses and adjustments were not always made for multiple sig nificance testing.
Conclusion
This prospective, randomised, controlled multicentre trial reports the first comparative evidence that BWD+PHMB and Ag have the potential to serve as treatment for local wound infections or, at least, as prophylaxis against systemic wound infections. As the antimicrobial properties of BWD+PHMB were shown to be significantly superior to those of Ag, combined with high user satisfaction and improvement in important aspects of the patients' quality of life, patients and health professionals can benefit from its use on critically colonised (wounds-at-risk) and locally-infected painful wounds. n
